ga naar hoofdinhoud
Informatie voor zorgverleners Behandelprotocollen Polycythemia vera (PV) Richtlijnen en literatuur

Richtlijnen

Klik HIER voor de richtlijn 'Polycythemia vera' van de HOVON CML - MPN werkgroep.

Literatuur

  1. Arber DA et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391-2405
  2. Khoury JD et al. The 5th edition of the World Health Oganization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 2022; 36:1703-1719
  3. Barbui T et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012; 120:5128–33
  4. Barbui T et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018 May; 32(5):1057-69
  5. Barosi G et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010; 148:961-3
  6. Emanuel RM et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012 Nov 20; 30(33):4098-103
  7. Gangat N et al. JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views. Leukemia 2021; 35(8), 2166–2181
  8. Harrison CN, Robinson SE. Myeloproliferative disorders in pregnancy. Hematol Oncol Clin North Am. 2011; 25:261-75
  9. Hamulyak EN et al. A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms. Blood Advances 2021; 5(1)113-121
  10. Landolfi R et al. European collaboration on low-dose aspirin in polycythemia vera investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350:114-24
  11. Loscocco GG et al. A JAK2V617F variant allele frequency greater than 50% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood 2021; 138 (supplement 1), 237
  12. Marchioli R et al. CYTO-PV collaborative group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013; 368(1):22-33
  13. McMullin, MF. Diagnostic workflow for hereditary erythrocytosis and thrombocytosis. Hematology (United States), 2019; (1)391–396
  14. Racca C et al. Aspirin intake in the morning is associated with suboptimal platelet inhibition, as measured by serum Thromboxane B2, during infarct-prone early-morning hours. Platelets 2019; 30(7):871-77
  15. Rocca B et al. A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood 2020; 136(2):171-82
  16. Riva N et al. Clinical approach to splanchnic vein thrombosis: risk factors and treatment. Thromb Res. 2012 Oct; 130 Supplement 1:S1-3
  17. Swerdlow SH et al. WHO classification of tumours of haematopoietic and lymphoid tissues, revised 4th edition. World Health Organiszation; 2017
  18. Tiede A et al. How I treat acquired von Willebrand syndrome. Blood 2011; 117(25):6777-8

 

Ga terug naar de PV homepage of lees meer over PV:

Ga terug naar de algemene homepage Behandelprotocollen.